Abstracts tagged "Hepatitis and rituximab"

Abstract Number: 2806 • 2013 ACR/ARHP Annual Meeting
Low Risk Of Hepatitis B Virus Surface Antigen Seroreversion In HBsAg Negative/Anti-Hbc Positive Carriers Undergoing Rituximab For Rheumatoid Arthritis
Valentina Varisco¹, Mauro Vigano'², Alberto Batticciotto¹, Pietro Lampertico³, Antonio Marchesoni⁴, Patrizia Gibertini⁴, Raffaele Pellerito⁵, Guido Rovera⁶, Roberto Caporali⁷, Monica Todoerti⁷, Michele Covelli⁸, Antonella Notarnicola⁸ and Piercarlo Sarzi-Puttini⁹, ¹Rheumatology, Rheumatology Unit, L. Sacco University Hospital, Milan, Italy, ²Hepatology, San Giuseppe hospital, University of Milan,, Milan, Italy, ³Gastroenterology, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, University of Milan,, Milan, Italy, ⁴Rheumatology, Istituto Ortopedico Gaetano Pini, Milano, Italy, ⁵Medicina II, Ospedale Mauriziano, Turin, Italy, ⁶Rheumatology, Ospedale Mauriziano, Turin, Italy, ⁷Rheumatology, Rheumatology, IRCCS Policlinico San Matteo Foundation and University of Pavia, Pavia, Italy, ⁸D.I.M.I.M.P, Rheumatology Unit - University of Bari, Bari, Italy, ⁹Rheumatology Unit, L. Sacco University Hospital, Milan, Italy
Background/Purpose: B cell-targeted therapy using rituximab (RTX), anti-CD20 monoclonal antibody, is an effective treatment for Rheumatoid arthritis (RA). However, the safety of such therapy in…
Abstract Number: 1612 • 2013 ACR/ARHP Annual Meeting
Rituximab For Treatment Of Refractory Auto-Immune Hepatitis
Chadi Rakieh¹, Edward M. Vital², Paul Emery³ and Michael Martin¹, ¹Rheumatology, Division of Rheumatic and Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, LTHT, Leeds, United Kingdom, Leeds, United Kingdom, ²Section of Musculoskeletal Disease, Division of Rheumatic and Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, LTHT, Leeds, United Kingdom, Leeds, United Kingdom, ³Division of Rheumatic and Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, LTHT, Leeds, United Kingdom, Leeds, United Kingdom
Background/Purpose: Auto-immune hepatitis (AIH), also known as lupoid hepatitis, is a chronic progressive disease of unknown aetiology. First-line therapy consists of corticosteroids alone or in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].